rs4220 — FGB Arg448Lys (R448K)

Missense variant in the fibrinogen beta chain that elevates circulating fibrinogen levels and alters fibrin network architecture, with sex-specific effects on hypertension risk in men

See your personal result for FGB

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

FGB Arg448Lys — Fibrinogen Beta Chain Variant Linking Clot Structure to Cardiovascular Risk

Fibrinogen is the principal protein of blood clotting. During coagulation, thrombin cleaves fibrinogen into fibrin monomers that polymerize into a mesh-like scaffold, which factor XIIIa cross-links into a mature clot. The fibrinogen beta chain (FGB)11 fibrinogen beta chain (FGB)
one of three polypeptide chains — alpha, beta, and gamma — that assemble into the fibrinogen hexamer; the beta chain contributes to the central E-domain that controls fibrin polymerization kinetics and fiber thickness plays a critical role in determining the mechanical properties of the resulting clot. rs4220 changes a single amino acid in the mature beta chain — arginine to lysine at position 448 — and this seemingly minor substitution affects both how much fibrinogen circulates and how the resulting fibrin network is structured.

The Mechanism

The p.Arg478Lys substitution (position 448 in the mature processed protein, after removal of the 30-residue signal peptide) replaces arginine — a positively charged amino acid with a long guanidinium side chain — with lysine, which is also positively charged but shorter. The change alters the charge distribution and steric properties of the fibrinogen beta chain in a region that participates in fibrin-fibrin lateral aggregation during clot formation. Studies in African populations found that rs4220 is among the FGB variants whose interaction with total fibrinogen levels significantly influences fibrin clot properties — including fiber thickness, clot density, and susceptibility to fibrinolytic breakdown — independently of fibrinogen concentration alone.

The A allele also associates with modestly elevated plasma fibrinogen levels. Fibrinogen is an acute-phase reactant22 Fibrinogen is an acute-phase reactant
plasma levels rise two- to five-fold during inflammation or infection, making fibrinogen both a structural clotting protein and a sensitive marker of systemic inflammation. Elevated fibrinogen from genetic causes — as distinct from acute inflammation — may alter the fibrin network formed during clotting, producing denser clots with increased resistance to plasmin-mediated dissolution.

The Evidence

A prospective cohort study of 1,294 Chinese participants followed for hypertension development identified rs4220 as a predictor of incident hypertension specifically in men33 A prospective cohort study of 1,294 Chinese participants followed for hypertension development identified rs4220 as a predictor of incident hypertension specifically in men
Ong et al. 2010 (Thrombosis and Haemostasis): among 178 men who developed hypertension from a normotensive baseline, the A allele conferred OR 1.52 (p=0.022); no significant association was found in women. The A allele was also independently associated with elevated baseline plasma fibrinogen levels (β=0.144, p<0.001), suggesting that the hypertension association is partly mediated through fibrinogen's effects on blood viscosity and endothelial shear stress.

A case-control study of 508 MI patients and 503 healthy controls in Chinese Han adults found the opposite direction of effect for coronary events44 A case-control study of 508 MI patients and 503 healthy controls in Chinese Han adults found the opposite direction of effect for coronary events
Lu et al. 2008 (Chinese Medical Journal): K allele (A allele) carriers (KK+RK vs RR) had adjusted OR 0.71 for MI (p=0.023). This apparent paradox — elevated fibrinogen yet reduced MI risk — is consistent with evidence that the structural quality of fibrin clots, not merely circulating fibrinogen levels, determines cardiovascular risk. The Arg→Lys substitution may alter clot architecture in ways that reduce plaque-related arterial thrombosis while separately influencing blood pressure through viscosity effects.

A Mendelian randomization analysis of FGB variants including rs4220 in a large Danish cohort found that fibrinogen-increasing alleles produced a ~7% higher plasma fibrinogen level, but this genetically elevated fibrinogen was not associated with venous thromboembolism risk (PE or DVT)55 A Mendelian randomization analysis of FGB variants including rs4220 in a large Danish cohort found that fibrinogen-increasing alleles produced a ~7% higher plasma fibrinogen level, but this genetically elevated fibrinogen was not associated with venous thromboembolism risk (PE or DVT)
Klovaite et al. 2013 (Am J Respir Crit Care Med). This Mendelian randomization finding argues against a causal role of fibrinogen levels in VTE, while leaving open a causal role in blood pressure regulation.

In a cross-sectional study of 480 community-dwelling adults, AA homozygotes at rs4220 showed approximately 12% lower carotid intima-media thickness (IMT) compared to other genotypes (Exp. β = 0.88, significant after adjustment for age, sex, BMI, exercise, and smoking)66 In a cross-sectional study of 480 community-dwelling adults, AA homozygotes at rs4220 showed approximately 12% lower carotid intima-media thickness (IMT) compared to other genotypes (Exp. β = 0.88, significant after adjustment for age, sex, BMI, exercise, and smoking)
Wu et al. 2020 (PLoS One), consistent with the Chinese MI study's finding of a protective effect for the minor allele.

Evidence level is moderate: multiple studies across diverse populations with consistent fibrinogen-level effects, but contradictory associations for different cardiovascular endpoints, sex-specificity of the hypertension finding, and limited replication in prospective Western cohorts.

Practical Actions

The primary clinically actionable finding for rs4220 A carriers is the sex-specific association with hypertension development. Men carrying the A allele who have elevated fibrinogen levels should monitor blood pressure and fibrinogen periodically. The evidence does not support major changes in supplementation for heterozygotes; the AA homozygote state may warrant more active monitoring. The mixed evidence on cardiovascular outcomes underscores that fibrinogen level alone is an imperfect risk marker — the structural function of the fibrin network matters independently.

Interactions

rs4220 lies in the same gene as the well-studied promoter variants rs1800787 (FGB -148C>T) and rs1800790 (FGB -455G>A), which independently raise fibrinogen levels. Concurrent elevation of fibrinogen from both coding and regulatory FGB variants would be expected to compound the fibrinogen-level phenotype. The Kotzé et al. 2015 study identified interactions specifically between rs4220 and total fibrinogen levels in determining fibrin clot structure, suggesting that the coding variant modifies how elevated fibrinogen translates into clot architectural changes.

The rs6050 (FGA Thr312Ala) and rs6063 (FGG Gly191Arg) variants in the fibrinogen alpha and gamma chains respectively, when present alongside rs4220, may compound fibrin network dysfunction beyond what any single variant predicts.

Genotype Interpretations

What each possible genotype means for this variant.

GG Normal

Common genotype — standard fibrinogen beta chain, no elevated fibrinogen effect from this variant

You carry two copies of the common G allele at rs4220. This is the reference genotype, present in approximately 69% of people globally. Your fibrinogen beta chain has the standard arginine at position 448, and fibrin polymerization is unaffected by this variant. Your fibrinogen levels and clot structure are not elevated by rs4220 specifically.

AG Elevated Fibrinogen Intermediate

One copy of the minor A allele — modestly elevated fibrinogen and sex-specific hypertension risk in men

The heterozygous AG genotype produces a mixture of fibrinogen molecules — some with the standard Arg448 beta chain and some with the Lys448 variant. The Lys substitution alters the charge and geometry of the beta chain at a site involved in lateral fiber aggregation during clot formation. Studies in African populations showed that rs4220 interacts with total fibrinogen concentration to influence fibrin clot properties, including fiber thickness and resistance to fibrinolysis, independent of fibrinogen levels alone.

The hypertension risk signal is sex-specific: the Ong et al. 2010 prospective cohort (Thromb Haemost, PMID 20135074) found significant association only in men, consistent with known sex differences in how fibrinogen affects vascular tone and endothelial shear stress. Women with this genotype do not appear to have a significantly elevated hypertension risk from rs4220 based on available data.

A Mendelian randomization analysis (PMID 23220916) confirmed that FGB variants including rs4220 raise circulating fibrinogen by ~7% but found no causal effect on venous thromboembolism, implying the biological consequences are concentrated in blood viscosity and arterial endothelial function rather than venous clotting risk.

AA High Fibrinogen High

Two copies of the A allele — highest fibrinogen elevation from this variant, with meaningful hypertension risk in men

The AA homozygous state means every fibrinogen molecule produced carries two copies of the Lys448 beta chain. The resulting fibrin network has altered fiber packing geometry and interaction with plasminogen activators. Kotzé et al. 2015 (Br J Haematol, PMID 25156046) demonstrated in a large African cohort that rs4220 participates in statistically significant interactions between fibrinogen concentration and clot properties — specifically, the variant modulates how a given fibrinogen level translates into a particular fiber thickness and clot density. In the AA state, this modulation is maximal.

The sex-specific hypertension finding (PMID 20135074) suggests a hormone- mediated interaction: testosterone-related differences in fibrinogen turnover, renin-angiotensin sensitivity, or endothelial shear-stress responses may amplify the fibrinogen-blood pressure link in men specifically. Women with AA genotype should not be alarmed — the evidence does not show a significant hypertension signal in females for this variant.

The finding that AA homozygotes have lower carotid IMT than expected (PMID 32214403) and that K allele carriers have lower MI risk (PMID 18982866) suggests that the Lys448 substitution may produce a fibrin network that is less prone to supporting arterial plaque-associated thrombosis, even while mildly elevating blood pressure through viscosity mechanisms. These divergent effects make the clinical picture for AA individuals nuanced: vigilance for hypertension in men, but without excess concern about atherosclerotic coronary events from this specific variant.